研究单位:[1]Huazhong University of Science and Technology[2]Tongji Hospital,Tongji Medical College Affiliated,Huazhong University of Science & Technology Wuhan,Hubei,China,430030
研究目的:
This is an open-label,single-arm, phase II exploratory study that evaluates the efficacy and safety of Camrelizumab combined with Chemotherapy (carboplatin or cisplatin + etoposide)and Apatinib as First Line treatment in Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas(EP-NEC)